To determine utility of practice of chest computed tomography (CCT) and bone scan (BS) in patients with early-stage hepatoma evaluated for transplantation (LT). Summary Background Data: Consensus-based policy mandates routine CCT and BS in LT candidates with hepatoma. No data exist either to support or refute this policy. Methods: From January 1999 to December 2002, stages I and II hepatoma patients evaluated at 4 centers were included. Scan interpretation was positive, indeterminate, or negative. Outcomes of evaluation and transplantation were compared between groups based on scans. Total charges incurred were derived from mean of charges at the centers. Results: One hundred seventeen stages I and II patients were evaluated. None had positive scans, 78 had negative, 29 had at least 1 indeterminate, and 10 did not have 1 or both scans. Twelve patients were declined listing, 6 from progression of hepatoma but none from CCT or BS findings. Two listed patients were delisted for progression of the hepatoma. Proportion of patients listed, transplanted, clinical and pathologic stage of hepatoma, and recurrence after LT were similar in groups with negative and indeterminate scans. Indeterminate scans led to 6 invasive procedures, 1 patient died of complications of a mediastinal biopsy, and none of the 6 showed metastases. Charges of $2933 were generated per patient evaluated. Conclusions: Positive yield of routine CCT and BS in patients with hepatoma is very low despite substantial charges and potential complications. CCT and BS performed only when clinically indicated will be a more cost-effective and safer approach. (Ann Surg 2005;241: 622-628) From the *
O utcomes of liver transplantation (LT) for hepatoma have improved remarkably during the past decade. [1] [2] [3] [4] [5] This improvement derived mainly from improved selection of patients (ie, rejection of patients for transplant candidacy who are at higher risk for cancer recurrence following LT. Concurrent with the improved outcomes, and more recently from changes in liver allocation policies, the number of patients with hepatoma who receive liver transplants in the United States has increased considerably over recent years. Most liver transplant programs use the Milan group's criteria for selection of patients with hepatoma for LT, and the same criteria form the basis of the United Network for Organ Sharing (UNOS) policy for selection of candidates with hepatoma for LT. 1, 6 In an effort to identify hepatoma patients with subclinical metastases to the lungs or bones a computed chest tomography (CCT) and whole body bone scan (BS) were added to the LT evaluation. This UNOS policy, (3.6.4.4) , effective August 19, 1998 , states: "The patient has known hepatocellular carcinoma and has undergone a thorough assessment to evaluate the number and size of tumors and to rule out any extrahepatic spread and/or macrovascular involvement (ie, portal or hepatic vein). The assessment of the patient should include ultrasound of the patient's liver, a computerized tomography or magnetic resonance imaging scan of the abdomen and chest and a bone scan." 6 Clinical data regarding the incidence of bone and lung metastases in patients with hepatoma are sparse. Consequently there are no evidence-based recommendations whether to screen patients with early stages of hepatoma routinely for distant metastases before treatment. The most effective method for such screening is unknown. 7, 8 Thus, the current UNOS policy requiring CCT or magnetic resonance imaging (MRI) and a BS in all hepatoma patients who undergo liver transplant evaluation is based on clinical consensus rather than evidence. Cost-effectiveness of diagnostic and therapeutic interventions is very important to maximize healthcare benefits within a finite budget. 9, 10 While the policy of mandatory CCT/BS in patients with hepatoma undergoing LT evaluation is intended to prevent inadvertent transplantation of a patient with subclinical thoracic and/or bone metastases, the cost/benefit analysis of such a practice has not been examined, to our knowledge.
The goals of this collaborative study among 4 liver transplant centers were to determine the positive yield of routinely performed CT chest and BSs in patients with stages I and II hepatoma undergoing a LT evaluation and to examine whether the data justify continuation of the current UNOS policy 3.6.4.4. Based on our personal observations, we hypothesized that the positive yield of routinely performed CCT/BS in patients with stages I and II hepatoma undergoing liver transplant evaluation is very low and that practice does not improve selection of patients for LT and therefore is not cost-effective.
MATERIALS AND METHODS
All patients with a diagnosis of stages I and II hepatoma who underwent liver transplant evaluation during the period January 1999 to December 2002 at 4 institutions are included in this retrospective study. The diagnosis of hepatoma was made on standard clinical and imaging criteria, ␣ fetoprotein levels, and biopsy. Routine biopsies were not performed. Patients in whom hepatoma was identified after listing but prior to LT were included in this cohort. The policy of mandatory CCT/BS is applicable to such patients. The patients in whom hepatoma was diagnosed at or after transplantation were excluded. The policy of mandatory CCT/BS could not be practiced in this group for obvious reasons. Two staging systems were used for this study. Because liver transplant programs in the United States follow the American Liver Tumor Study Group Modified Tumor Node-Metastases Staging Classification (referred herein as the UNOS system) to assess and select hepatoma patients for LT, this staging was employed to determine eligibility for inclusion/exclusion into this study. 6 Only stages I and II patients were included. To provide an additional perspective, once included, the patients were further staged by a more widely accepted Tumor Node Metastases system of the American Joint Commission on Cancer. 11 Both staging systems are further elaborated in Table 1 . The LT evaluation was conducted according to each center's practice. The algorithm depicted in Figure 1 was followed for both chest imaging and BSs. A majority of CCT were performed at the liver transplant centers with or without intravenous contrast and with the equipment and technique standardized at each institution. If a CCT was contraindicated, an MRI of the chest was substituted. Whole body BSs were performed following injection of 99 technetium utilizing equipment and technique standard at each institution. The results were reported by more than 1 radiologist at each institution. In the few cases in which CCT/BS were performed outside the transplant centers, the films were reviewed again by one of the radiologists at the respective liver transplant center. A majority of the patients with an indeterminate result underwent repeated study several weeks later. Patients with findings considered very suspicious for metastases were further investigated with a biopsy.
Upon completion of the evaluation transplant listing outcomes were categorized as (1) accepted for transplant listing; (2) declined for transplant listing due to advanced HCC; and (3) declined for transplant listing for non-tumorrelated reasons. Rejection for either tumor or non-tumorrelated reasons, while following general guidelines practiced by the transplant community, was based on individual institution's practice. Records were scrutinized to identify hepatoma patients declined for transplantation based on the findings of CCT/BS. Outcomes of patients after listing, as of December 1, 2003, were categorized as (1) transplanted; (2) waiting for a transplant; (3) removed from the waiting list for tumor progression; or (4) removed from the waiting list for other reasons (including death on the waiting list). Practices of donor selection, surgical techniques, postoperative management including immunosuppression, and screening for hepatoma recurrence followed each institution's protocols. After transplantation, the disease stage was determined from histologic examination of the liver explants. Patients that developed recurrence of hepatoma were identified and their survival was assessed.
A mean of the charges for CCT with contrast and BS at each of the 4 participating centers was used to compute the charges incurred by the practice of this routine policy. The charges for each of the procedures included the cost of doing the procedure (equipment, disposables, and personnel) plus the markup. Physician fees were not included. Chest MRI was assigned the same charge as CCT. Charges for the additional scans performed to address an indeterminate initial result were included. Charges for the Invasive procedures performed as a result of the scan were not included. Data were analyzed to determine the positive, indeterminate, and negative yield of the scans performed and patient outcomes in the different groups. The significance of the differences observed between the groups was examined by Fisher exact test with Yates correction. Significance levels were set at P Ͻ 0.05. programs. From this cohort, 117 patients with UNOS stages I and II hepatoma and cirrhosis were evaluated for LT. Another group of 22 patients who were found to have hepatoma in the liver explants but in whom this diagnosis was not suspected before the transplant were excluded. The clinical characteristics of the 117 patients are shown in Table 2 . A majority of patients had UNOS stage II, AJCC stage I disease, and in 60% hepatitis C was the only or the principal cause of liver disease. Women comprised only 18% of the patient population. The listing outcome of the entire group of 117 patients and progression of their clinical course after listing are shown in Figure 2 . Our data show the majority of patients were accepted for the transplant wait list. Only 12 (10%) patients were declined, 6(5%) because of progression of hepatoma and 6 (5%) for non-hepatoma-related reasons. Of note, none of those declined because of hepatoma had metastases that were detected on routinely performed scans.
Data on scans performed are shown in Table 3 . None of the scans were frankly positive. Nineteen percent and 9% of the CCT and BS, respectively, were judged indeterminate. A total of 78 patients had both scans reported negative, and in 29 patients at least 1 of the 2 scans (CCT/BS) was reported indeterminate.
Because several etiologies cause nodules on a CCT and/or increased uptake in a BS, we considered the possibility that some indeterminate scans might represent metastatic disease and thus should be considered positive. We examined I  T2N0M0  Stage II  II  T3N0M0  Stage III  III A  T4N0M0  IVA1: T4a N0M0  IIIB  IVA2: T4bN0M0 IIIC: Any T N1M0 IVB: Any T, any N1, any M1 IV: Any T, any N and M1 *A modified tumor node metastasis (TNM) staging developed by the American Liver Tumor Study Group and adopted by the United Network for Organ Sharing (UNOS) 6 was used to select stages I and II patients for liver transplantation. A comparison is provided with a more widely recognized TNM staging system adopted by the American Joint Commission on Cancer (AJCC). 11
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Annals of Surgery • Volume 241, Number 4, April 2005 this possibility from 3 different perspectives by comparing the groups with negative and indeterminate scans, and the results are shown in Table 4 . First, we examined whether both groups were comparable in disease status. Sixty-eight percent of those in the negative-scan group had UNOS stage II compared with 79% in the indeterminate group (24% versus 28% AJCC stage II disease). After LT evaluation was completed, 4 of 78 (5%) and 1 of 29 (3%) patients with negative and indeterminate scans, respectively, were not accepted due to progression of hepatoma. To further address whether patients with indeterminate scans had more advanced hepatoma than those with negative scans, we examined the proportion of those transplanted in both groups that were upstaged following histologic examination of the liver explants. Data in Table 4 show that 10 of 63 (16%) patients in the group with negative scans versus 3 of 20 (15%) the group with indeterminate scans that received LT had pathologic stage III and IV (UNOS) disease (3 versus 5% with AJCC system) in the explants. None of these differences were statistically significant. Thus, both groups have comparable stages of disease both at the time of evaluation and at transplantation. There were 13 patients in both the groups in whom the liver explant showed no evidence of hepatoma. We have not excluded those patients from this study for the following reasons. All of them except a single patient with ␣ fetoprotein Ͼ500 ng/mL had imaging findings consistent with hepatoma, and the algorithm for scans mandated by UNOS was followed. Six of these patients had histologic proven hepatoma on biopsy, and they were treated by nonsurgical ablation prior to transplantation and thus had complete ablation of the tumor. The protocol of sectioning of the liver explant was not standardized, and a few small tumors could have been missed due to the thickness of the sections exceeding the diameter of the tumor. Second, if truly positive CCT/BS scans were interpreted as indeterminate and patients were accepted for transplant listing, one would expect to find progression of chest and bone metastatic disease over the several months that listed patients wait for a transplant. Our data show that 2 of 71 (3%) patients listed with negative scans were removed for progression of hepatoma by abdominal imaging in contrast to none in the group with indeterminate scans. However, when the waiting time for transplantation is short, an adequate NA indicates not available. *One patient had no tumor seen in the imaging studies but was accepted for transplant listing as a hepatoma based on the ␣ fetoprotein level Ͼ500 as per UNOS criteria. Although complete information was not available to determine the exact stage of the disease, records indicated that the tumor characteristics fulfilled UNOS stage I/II criteria.
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Chest CT and Bone Scan in Hepatoma period of time may not elapse for metastases to become clinically apparent. The patients that received liver transplants in our study waited for the organ a median of 98 days (mean 307 Ϯ 483 days). Finally, if some of the indeterminate-group patients with hepatoma had true metastatic disease and such patients received LT, then one would expect a higher rate of recurrence of hepatoma following transplantation compared with the patients with negative scans. Patients that received liver transplants in this study had a median follow-up of 511 days (mean 615 Ϯ 439 days). Table 3 shows that after transplantation, 4 of 78 (5%) and 2 of 29 (7%) with negative and indeterminate scans, respectively, developed recurrence; this difference was not significant. Therefore, it is extremely unlikely that the indeterminate results of routinely performed CCT/BS represent true metastatic disease.
In addition to the initial scans, hepatoma patients underwent an additional 41 CCTs and 45 BSs. Based on the results of the CCT/BS, 6 invasive procedures were performed, all in the group with indeterminate result. One patient had a bone biopsy. Table 5 . Considerable variation existed in the charges for each of the 2 scans among the 4 centers, despite the fact that they were in close geographic proximity in the Northeastern part of the United States. Therefore, a mean of the charges was judged more meaningful. Without inclusion of physician fees for the interpretation of the scans, $343,216 total and $2933 per patient charges were incurred as a result of routine performance of CCT and BS in patients with stages I and II hepatoma during evaluation for an LT. 
DISCUSSION
The results of LT for hepatoma have improved remarkably in the last decade, mainly from improved selection of patients for transplantation rather than any advances in adjuvant therapy. [1] [2] [3] [4] [5] Patients who develop a recurrence after LT almost certainly do so from dissemination and growth of extrahepatic disease present at the time of transplantation. The current consensus-based policy of routine CCT/BS in the evaluation of patients with stages I and II hepatoma for LT presupposes that such evaluation will identify a significant number of patients with subclinical extra-abdominal disease and thereby avoid futile transplantation of such patients. This policy should improve both the utilization of donor livers and the outcomes of patients who receive LT for hepatoma by avoidance of transplantation of patients with occult disseminated disease. Our data do not support these concepts. The positive yield of either CCT or BS in our series of patients with stages I and II hepatoma was zero. Further, initial scans performed under the UNOS policy did not contribute to exclusion of any patients from transplant listing.
Data regarding the incidence of bone and lung metastases in patients with HCC are limited in the literature. 7, 8, 12 In autopsy studies collected from 7 reports, comprising 1497 subjects, lung and bone metastases were present in 44% and 8%, respectively. 7 Most of the subjects in these reports had very advanced tumors, unlike the majority of patients who receive liver transplants under the current UNOS policy. In 15 patients with tumors smaller than 5 cm, who are similar to our UNOS stages I and II patients being evaluated for LT, only 1 patient (7%) had autopsy evidence of hematogenous metastases. 12 In a clinical study of 300 patients with unresectable hepatoma, skeletal metastases were detected in 7.3%. 8 The preceding data from reports of patients with extensive disease have limited applicability in the development of clinical practice policies, especially for patients with early stages of disease such as LT candidates. Thus, our study is the first to examine the prevalence of thoracic and skeletal metastases by routine screening of patients with stages I and II hepatoma and shows the absence of clinically detectable thoracic and bone metastases in these patients.
Furthermore, data from the literature pertaining to the prevalence of lung and/or bone metastases in patients with early stages of other malignancies provide additional information in critically examining the existing policy of mandatory CCT/BS in patients with hepatoma. Kronawitter et al 13 reported a very low positive yield of 2% in the detection of lung metastases with a CCT in 202 patients with resectable liver metastases from colorectal cancer. Of note, 15 of 17 subjected to invasive procedures as a result of CCT findings had benign lesions. In 673 women with T 1-2 N 0 M 0 breast carcinoma, routine BS at the time of diagnosis determined an initial metastases detection rate of 0.44% and an overall accuracy rate of 3.9%. 14 Present constraints on healthcare spending require critical examination of the cost-effectiveness of each diagnostic and therapeutic intervention. Once again, data from the literature on the cost-effectiveness of routine screening with imaging studies in early stages of other malignancies provide some guidance. Routine CCT was shown not to be costeffective in detecting lung metastases in 125 patients with extremity T1 soft-tissue sarcoma and in 600 patients with nonthoracic sarcomas. 15, 16 The respective incremental costeffectiveness ratios in these 2 studies were $59,772 and $27,594 per patient detected with lung metastases. Similar investigations have been performed regarding the cost-effectiveness of routine use of BSs in patients with newly diagnosed early-stage breast cancer. 17, 18 One study showed $277,798 were spent in detecting 1 patient with subclinical bone metastases. 18 Such studies have led to revision of clinical practice policies, with considerable savings to the healthcare system. 19 While it is difficult to determine the dollar amount justifiable to avoid futile transplantation and the value of increasing appropriate utilization of a donor liver, our study shows that $2933 charges were generated without detection of even 1 patient with subclinical metastases.
Therefore, the policy of routine CCT and BS in patients with stages I and II hepatoma patients undergoing LT is not cost-effective. Furthermore, some patients were subjected to unnecessary invasive procedures because of indeterminate findings of the imaging studies based on this policy. Although the number of patients subjected to invasive procedures for what eventually proved to be benign problems is small in our study, the coagulopathy that is very often present in LT candidates with hepatoma and cirrhosis renders any invasive procedure very risky. This risk is exemplified by the death of 1 patient as a direct result of the biopsy for what turned out eventually to be a nonmalignant problem. Although our study population was composed entirely of hepatoma patients considered for LT, our results are also applicable to stages I and II hepatoma patients considered for treatment with modalities other than transplantation, such as hepatic resection.
Our study's limitations and drawbacks need to be discussed. First, our study used charge data, which are easier to obtain, rather than cost data. Charges are more variable than costs and are a less-accurate reflection of the true costs incurred by the healthcare system due to the considerable variation from one institution to another, as exemplified by our own data. Second, there is likely to be inter-and intrainstitutional variability in both technique and interpretation of CCT/BS. On the other hand, our study does reflect the day-to-day practice in most liver-transplant programs, and thus the data are more likely to be representative of a much broader section of patients with hepatoma being evaluated for LT. Finally, our findings are limited only to patients with Annals of Surgery • Volume 241, Number 4, April 2005 Chest CT and Bone Scan in Hepatoma early stages of hepatoma. Further studies are needed to examine the utility of routine CCT/BS in patients with more advanced tumors if criteria for LT are liberalized in patients with hepatoma.
In conclusion, the positive yield of routinely performed CCT/BS in LT candidates with stages I and II hepatoma is negligible and thus does not improve the selection of patients for LT. Furthermore, such a practice incurs substantial charges and costs to the healthcare system and subjects a few patients to unnecessary invasive procedures, with potential for serious morbidity and even mortality. We propose that a chest radiograph be substituted for the routine CCT and BS. Chest CT should be reserved for patients with suspicious findings on a chest radiograph and BS performed when clinically indicated. Finally, we propose a revision of U.N.O.S. policy 3.6.4.4.
